Hua-Ming Li

Hua-Ming Li

Auto-generated profile, based on publicly available information

Hua-Ming Li

Department of Thoracic Surgery, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in The FASEB Journal
Verified
Journal Article
Closed access
HCHuoying Cai
Huoying Cai
HLHuaming Li
Huaming Li
XXXiaoyong Xiao
Xiaoyong Xiao
SWSiwen Wang
Siwen Wang
RLRuiming Liu
Ruiming Liu
CYChen Yao
Chen Yao

1 November 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
BKBi-Ang Kang
Bi-Ang Kang
LZLei Zhang
Lei Zhang
XDXiaoying Duan
Xiaoying Duan
BJBo Jiang
Bo Jiang
YZYi-Qian Zhang
Yi-Qian Zhang
HLHua-Ming Li
Hua-Ming Li
Background and Objective: Bronchoscopic Thermal Vapor Ablation (BTVA) is a novel endoscopic lung volume reduction (ELVR) technique designed to target emphysematous segments and reduce lung hyperinflation, especially in patients with heterogeneous emphysema. Although previous studies have demonstrated its efficacy in Western populations, data regarding BTVA outcomes in Asian cohorts remain limited. This study aimed to evaluate the short-term efficacy and safety of BTVA in patients with severe COPD in a real-world clinical setting. Methods: This single-center, retrospective, observational study included 8 patients with advanced COPD who underwent BTVA at the Eighth Affiliated Hospital of Sun Yat-sen University between May 2023 and December 2024. Pulmonary function (FEV1, FVC, FEV1/FVC), 6-minute walk distance (6MWD), dyspnea scores (mMRC, CAT), and CT-based lung volume changes were assessed at baseline and at 1, 3, and 6 months post-treatment. Procedure-related adverse events were monitored for 1 month, and all patients were followed up for 6 months. Results: All patients completed the 6-month follow-up. Significant improvements in FEV1, FVC, 6MWD, and clinical symptoms (CAT and mMRC) were observed as early as 1 month post-BTVA and were sustained through 6 months. Although FEV1/FVC showed no statistically significant change at 1 and 3 months, a significant increase was detected by month 6. CT imaging at 6 months revealed a marked reduction in the targeted lung volume from 707.5 ± 115.74 mL to 335.5 ± 129.59 mL. No severe adverse events were reported. Conclusion: BTVA appears to be a safe and effective minimally invasive intervention for selected patients with advanced COPD, leading to significant short-term improvements in lung function, exercise capacity, and hyperinflation. These findings support the clinical utility of BTVA in Asian populations, although larger prospective studies are needed to confirm long-term benefits and assess repeatability.